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Together with efforts aimed at early diagnosis, the identification of a molecular marker able to pave the way for a novel therapeutic approach can be an effective way toward reducing the high mortality of HNSCC. HER2 may represent such a marker, and its role as a biomarker in HNSCC is being studied, [3] with one related study being published in this issue. [4] Although data regarding the association between HER2 expression and the tumor-node-metastasis (TNM) stage is not conclusive, it is still possible that HER2 expression might be useful clinically. For example, it may identify a different subtype of HNSCC which may have its own therapeutic options, molecular pathogenesis, or prognosis.
For example, in some studies, HER2 has been shown to correlate with other clinicopathological parameters, such as disease-free survival. [5, 6] This may represent a different biologic behavior displayed by HNSCC's with HER2 overexpression. Such different biologic behavior is supported by other observations, for example, that HER2-positive clones tend to be selected -and sometimes enriched -in metastases. [7] As for therapeutic implications, it has been observed that HER2 positivity may play a role in chemo-radioresistance of HNSCC. [4] If confirmed by further studies, such finding may make HER2 an important and clinically relevant prognostic marker independent from the TNM stage and histological grade. Different therapies may be employed in HER2-positive HNSCC, the most obvious of which -HER2 inhibitors -is currently being studied in clinical trials. However, even if HER2-positive HNSCC's were not responsive to HER2-inhibitor therapy, identifying them may still shed light on the molecular pathogenesis of a subtype of HNSCC and thus possibly lead to a different therapy, more effective or safer than the current regimens.
For example, some studies have proposed a role for HER2 overactivation in the mechanism behind resistance to cetuximab treatment. [8] In parallel, some evidence suggests that HER2 inhibitors may be synergistic with EGFR-targeted therapy in treating HNSCC, possibly by overcoming such resistance. [9] Another important point raised in the article in this issue is the possibility that subdividing HNSCC by location may provide more significant results. [4] Aggregating all squamous cell carcinomas of the head and neck into the HNSCC group may not render justice to some peculiar subtypes which may have independent molecular pathogenesis, response to therapies and prognosis.
In conclusion, efforts aimed at reducing the mortality of HNSCC are direly needed. A novel biomarker such as HER2 may represent the fruit of such efforts, and more studies aimed at clarifying its role as a biomarker in HNSCC are awaited.
